Detection of Human Dermatopontin by Western Blot.
Western blot shows lysates of human heart tissue. PVDF Membrane was probed with 1 µg/mL of Human Dermatopontin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4629) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for Dermatopontin at approximately 22 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8.
Preparation and Storage
Sterile PBS to a final concentration of 0.2 mg/mL.
Reconstitution Buffer Available
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Dermatopontin, also known as TRAMP (tyrosine rich acidic matrix protein), is a widely expressed noncollagenous protein component of the extracellular matrix (1, 2). Mature human Dermatopontin shares 96%, 92%, and 92% amino acid sequence identity with bovine, mouse, and rat Dermatopontin, respectively. It is a 22 kDa molecule that is tyrosine sulfated but not glycosylated (3, 4). Dermatopontin contains three disulfide bonded loop structures that enclose conserved hexapeptide motifs (5). It accelerates collagen fibril formation in vitro, and Dermatopontin deficient mice exhibit altered collagen matrix deposition and organization (6 - 8). Dermatopontin is downregulated in fibrotic growths such as leiomyoma and scar tissue (9, 10). It binds both TGF-beta and the proteoglycan decorin, interactions that can increase the bioavailability of TGF-beta (11, 12). Dermatopontin promotes bone mineralization under the control of the vitamin D receptor and inhibits BMP-2 effects on osteoblast precursors (13, 14).
Okamoto, O. and S. Fujiwara (2006) Connect. Tissue Res. 47:177.
Superti-Furga, A. et al. (1993) Genomics 17:463.
Forbes, E.G. et al. (1994) FEBS Lett. 351:433.
Cronshaw, A.D. et al. (1993) Matrix 13:255.
Neame, P.J. et al. (1989) J. Biol. Chem. 264:5474.
MacBeath, J.R.E. et al. (1993) J. Biol. Chem. 268:19826.
Takeda, U. et al. (2002) J. Invest. Dermatol. 119:678.
Cooper, L.J. et al. (2006) Invest. Opthalmol. Vis. Sci. 47:3303.
Catherino, W.H. et al. (2004) Genes Chromosomes Cancer 40:204.
Kuroda, K. et al. (1999) J. Invest. Dermatol. 112:706.
Okamoto, O. et al. (1996) J. Biochem. 119:106.
Okamoto, O. et al. (1999) Biochem. J. 337:537.
Pochampally, R.R. et al. (2007) J. Bone Miner. Res. 22:1338.
Behnam, K. et al. (2006) Connect. Tissue Res. 47:271.
Entrez Gene IDs:
1805 (Human); 56429 (Mouse); 289178 (Rat)
Dermatopontin; DPT; Eq1; TRAMP; Tyrosine-rich acidic matrix protein
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.